Noxxon Pharma AG added €37 million (US$50.3 million) to its coffers in a Series C round that will enable the company to take its two lead programs, NOX-E36 and NOX-A12, into development for lupus nephritis and diabetic retinopathy, respectively, through clinical proof of concept. (BioWorld International)